E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of moderate to severe chronic bone pain related to metastatic cancer. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049038 |
E.1.2 | Term | Metastatic bone pain |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the analgesic efficacy of flexibly-dosed Pregabalin compared with placebo, in the adjunctive treatment of subjects with cancer-induced bone pain as add-on therapy to standard-of-care opioids for moderate to severe pain due to bone metastases. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of Pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: 1. Personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study entry. 2. Males/Female subjects aged ≥18 years 3. Females of childbearing potential must not be lactating, have a negative serum β-HCG pregnancy test, be surgically sterile or be practicing an effective form of contraception. Acceptable methods of contraception are as follows: a. Hormonal (oral, injectable or transdermal contraceptives). b. Barrier method with spermicide. c. Intrauterine device (IUD). d. Complete abstinence may be considered acceptable, but must first be discussed on a case-by-case basis with the Pfizer Medical Director and Pfizer Clinical Monitor prior to any screening tests for the study. 4. The subject must have a malignant, solid tumor that has been diagnosed as having metastasized to bone. The patient must be able to identify a reference site for pain. Radiographic or scintographic confirmation of site of the painful bone metastases (obtained within 60 days of screening) is required. 5. The subject’s mental status is sufficient to complete efficacy and tolerability scales and assessments. 6. Subject is willing and able to comply with scheduled visits, treatment plan, screening laboratory tests and other trial procedures. 7. Subject must have a daily worst pain at the reference site score of at least 4 on an 11- point anchored scale at Screening (Visit 1). 8. The subject has a performance status score of 0-2 (inclusive) as measured by the ECOG. 9. Life expectancy ≥3 months from start of the study 10. Creatinine Clearance ≥30 mL/min as calculated by the Cockcroft-Gault equation. 11. Total white blood cell count >1500 per cubic millimeter; platelet count ≥50 x103 per cubic millimeter. 12. If applicable, stable (initiated ≥ one month prior to Screening) chemotherapy treatment, and no initiation of new chemotherapy regimen planned over course of the study. 13. If applicable, radiotherapy or radiopharmaceutical treatment to the target lesion initiated ≥15 days prior to Screening, and no initiation of new therapy planned to target lesion over course of study. 14. If applicable, stable bisphosphonate therapy (ie, initiated more than two months prior to Screening) and no new bisphonsponate therapy planned over course of study. 15. Subject must have an average ‘Daily Worst Pain’ score of ≥4 at the reference site (as recorded in the daily diary) in the week preceding randomization (minimum 4 data points); and 16. Subject must be treated with opioid therapy such that he/she takes a constant daily dose of opioid (SR or IR), with ≤4 doses IR opioid per day allowed as rescue medication in the week preceding randomization; and 17. Subject must not be experiencing intolerable side effects from the total daily dose of opioids (eg, dose limiting side effects in the opinion of the patient and/or investigator). |
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following are not to be included in the trial: 1. Participation in previous clinical trials for Pregabalin. 2. A previous history of intolerance or hypersensitivity to Pregabalin, Gabapentin or drugs with similar chemical structure. 3. Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to screening. 4. Illiterate or unable to complete subject-rated assessment scales. 5. The subject has back pain that, in the clinical judgment of the investigator, is related to mechanical or radicular causes. 6. The subject has undergone diagnostic or therapeutic invasive interventions (angiography, biopsy, surgery) less than 15 days prior to study start that would impact their assessment of pain at the reference pain site or area, in the opinion of the investigator. 7. Use of antiepileptic drugs, current Gabapentin or Pregabalin use, or the initiation of disallowed analgesic and other therapies during the trial. 8. The subject is physically, psychologically, or mentally unable to comply with treatment protocol (such as an inability to swallow tablets or tolerate oral medication, or intractable nausea and vomiting) or perform study procedures. 9. The subject has a history of significant alcohol, analgesic or narcotic substance abuse within 6 months prior to screening as defined by DSM-IV-TR® criteria. 10. The subject has a known current seizure disorder. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the change in the “worst pain” score from baseline to the “worst pain” score during the fixed dose period at the reference site. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The End of Trial in all participating countries is defined as Last Subject, Last Visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |